Alzheimer’s disease: FDA guidance had ‘strong influence’ on endpoint selection
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticals